Citi lowered the firm’s price target on Biomea Fusion (BMEA) to $6 from $7 and keeps a Buy rating on the shares following the Q3 report. The firm cites the company’s higher spending and dilution from the recent public offering for the target drop.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: